Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 23, 2026, 12:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 17 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Vortioxetine Clear all

Conditions: Binge Eating Disorder
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Depression
Interventions: Clemastine Fumarate, Placebo; Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 60 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Volunteers
Interventions: Vortioxetine, Paroxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 15
States / cities: Encino, California • Long Beach, California • Torrance, California + 12 more

Conditions: Depression
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 7 Years to 11 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Long Beach, California • Atlanta, Georgia • Plano, Texas

Conditions: Healthy
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Social Anxiety Disorder, Major Depressive Disorder
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: The Medical Research Network; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20mg/day, Placebo; Drug · Other
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 7 Years to 11 Years
Enrollment: 683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 34
States / cities: Little Rock, Arkansas • Imperial, California • Lemon Grove, California + 29 more

Conditions: Panic Disorder
Interventions: Vortioxetine; Drug
Lead sponsor: Siyan Clinical Corporation; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Santa Rosa, California

Conditions: Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions: Not listed
Lead sponsor: Genelex Corporation; Industry
Eligibility: 65 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more

Conditions: Post-Traumatic Stress Disorder
Interventions: Placebo, Vortioxetine; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Miami, Florida • Atlanta, Georgia

Conditions: Depression, Menopause, Vasomotor Disturbance, Hot Flashes, Sleep
Interventions: vortioxetine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 62 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depressive Disorder, Major
Interventions: vortioxetine (Lu AA21004), Duloxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 62
States / cities: Tucson, Arizona • Little Rock, Arkansas • Bellflower, California + 59 more

Conditions: Type2 Diabetes, Major Depressive Disorder
Interventions: Vortioxetine; Drug
Lead sponsor: Todd Doyle; Other
Eligibility: 40 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Major Depressive Disorder, Coronary Artery Disease
Interventions: Vortioxetine; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: vortioxetine 10 mg tablet, vortioxetine 20 mg tablet, Placebo tablet; Drug · Other
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 15
States / cities: Beverly Hills, California • Garden Grove, California • National City, California + 11 more

Conditions: Severe Hepatic Impairment
Interventions: Vortioxetine; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Major Depressive Disorder
Interventions: Vortioxetine; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years and older
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 31
States / cities: Dothan, Alabama • Tucson, Arizona • Newport Beach, California + 27 more

Search by objective public record fields.

Vortioxetine for Binge Eating Disorder

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

Vortioxetine to Prevent Return of Symptoms in Children With Depression

Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults

Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)

A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder

YouScript IMPACT Registry

Vortioxetine for Posttraumatic Stress Disorder

Vortioxetine for Menopausal Depression

Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder

Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes

Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease

Investigating the Effect of Vortioxetine in Adult ADHD Patients

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

Real-life Effectiveness of Vortioxetine in Depression